From bronchitis to rhinosinusitis: new evidence and therapeutic horizons for Atusin® (ARINA)

Clinical efficacy was evaluated through the ARINA trial, an open-label, prospective real-world study involving 624 patients treated with Atusin® CAP. Over a 10-day period, total symptom severity decreased by 78%, with modified SNOT-22 scores decreasing from 34.54 to 7.66 points. Significant alleviation of nasal congestion, headache, and sputum thickness was recorded consistently, regardless of whether concomitant antibiotics were administered. Quality of life improved by 81.3%, with 97.3% of participants identified as clinical responders. Adverse events were negligible, occurring in less than 2% of cases. The findings demonstrate that the multimodal action of Atusin® CAP effectively facilitates mucolysis and reduces mucosal edema. This investigation confirms that the product provides a robust clinical benefit by restoring physiological defense mechanisms, offering a reliable therapeutic strategy and comprehensive pathophysiological approach for acute rhinosinusitis in primary care.